Form 4 for GALT GALECTIN THERAPEUTICS INC
Accepted 2025-09-15 00:00:00 ET · period of report 2025-09-12 · accession 0001133416-25-000038 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2025-09-15 | 2025-09-12 | GALT | LEWIS JOEL | Pres, CEO, Dir | S - Sale+OE | $6.36 | -14.0K | 832.6K | -2% | -$89.0K |
| DT | 2025-09-15 | 2025-09-12 | GALT | LEWIS JOEL | Pres, CEO, Dir | M - OptEx | $2.39 | +14.0K | 846.6K | +2% | +$33.5K |
| DT | 2025-09-15 | 2025-09-12 | GALT | LEWIS JOEL | Pres, CEO, Dir | M - OptEx | $2.39 | -14.0K | 40.2K | -26% | -$33.5K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-09-12 | S | D | 14,000 | $6.36 | 832,592 | D | — | — | (F2) The shares were sold in multiple transactions at prices ranging from $6.331 to $6.51. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. |
| 2 | Common | Common Stock | 2025-09-12 | M | A | 14,000 | $2.39 | 846,592 | D | — | — | |
| 3 | Derivative | Stock option (right to buy) | 2025-09-12 | M | D | 14,000 | $2.39 | 40,250 | D | $2.39 · 2018-12-14 to 2027-12-14 | 14,000 Common Stock | (F3) The options vested 100% on December 14, 2018. |